Expert Interview
Assessing ALX Oncology's Advancements with Evorpacept in Combatting HER2-Positive Gastric Cancer
Ticker(s): ALXOAn oncologist specializing in gastric cancers, particularly those with a focus on HER2-Positive cases, who is well-versed with the recent developments in immuno-oncology and the role of CD47 blockers in treatment.
The Phase 2 ASPEN-06 interim analysis showed an ORR of 52% for the evorpacept combination treatment compared to 22% for the control group. What factors contributed to this significant difference in response rates between the two groups?
Added By: slingshot_insightsWith the mDOR not yet reached for the evorpacept combination treatment arm and being 7.4 months for the control group, what implications does this have for the long-term efficacy of evorpacept in treating HER2-positive gastric/GEJ cancer?
Added By: slingshot_insightsThe safety profile of evorpacept was consistent with previous clinical trials and was well-tolerated. Were there any specific adverse events or side effects observed that could impact its future use?
Added By: slingshot_insightsThe interim results showed favorable efficacy compared to the RAINBOW study's results for CYRAMZA + paclitaxel. How does evorpacept's performance set it apart from other treatments in the same category?
Added By: slingshot_insightsDr. Sophia Randolph mentioned evorpacept's potential as a "first-in-class foundational immunotherapy." Can you elaborate on what this means and how it differentiates evorpacept from other therapies in the market?
Added By: slingshot_insightsThe ASPEN-06 trial allowed for patients who had prior treatments with KEYTRUDA (pembrolizumab) and ENHERTU. How did the inclusion of patients with these prior treatments impact the trial's results, and what does it suggest about evorpacept's efficacy in a diverse patient population?
Added By: slingshot_insightsWith the final analysis of the Phase 2 ASPEN-06 study expected in Q2 2024 and the initiation of the Phase 3 portion in late 2024, what are the key milestones and expectations for evorpacept's development pipeline in the coming years, and what is your view of that?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
